Brokerage firm Citi expects Sun Pharma’s innovation revenues to climb to $3.2 billion by FY30, up from $1.2 billion in FY25.
Brokerage firm Citi expects Sun Pharma’s innovation revenues to climb to $3.2 billion by FY30, up from $1.2 billion in FY25.